tenapanor — CareFirst (Caremark)
Reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy
Preferred products
- PhosLo
- Renvela
- Velphoro
Initial criteria
- Patient is an adult with chronic kidney disease (CKD) on dialysis
- Drug is being prescribed to reduce serum phosphorus as add-on therapy
- ONE of the following: patient has experienced an inadequate treatment response to phosphate binders (e.g., PhosLo, Renvela, Velphoro, etc.) OR patient has experienced an intolerance to any dose of phosphate binder therapy (e.g., PhosLo, Renvela, Velphoro, etc.)
Approval duration
12 months